A lesson from the EPO mess: stop the cost shifting.
Amerling
Richard
R
D000740:Anemia / Q000209:etiology / Q000628:therapy*; D003361:Cost Allocation; D011307:Drug Prescriptions / Q000191:economics; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000191:economics* / Q000627:therapeutic use; D006397:Hematinics / Q000191:economics* / Q000627:therapeutic use; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications*; D006278:Medicare / Q000458:organization & administration; D011994:Recombinant Proteins; D012051:Reimbursement Mechanisms / Q000458:organization & administration*; D006435:Renal Dialysis / Q000191:economics; D014481:United States
D006397:Hematinics; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068817:Epoetin Alfa